Arcus Biosciences drew a bullish assessment from Mizuho analyst Salim Syed on October 20, 2026, after presenting new data for its investigational kidney cancer drug casdatifan. Syed maintained an Outperform rating and a $47 price target, arguing that the market was not fully recognizing the drug’s potential as an initial treatment for clear cell renal cell carcinoma.
Key Takeaways
- Mizuho’s Salim Syed estimated casdatifan’s peak unadjusted sales potential at $4 billion.
- Arcus reported first-line combination results that support further late-stage testing, not regulatory approval.
- The company plans to start its Phase 3 PEAK-20 trial by the end of 2026.
Table of Contents
- Arcus Biosciences gains support for first-line opportunity
- What the clinical update established
- Phase 3 trials will test the broader development case
- Conclusion
Arcus Biosciences gains support for first-line opportunity
Syed’s investment case distinguishes between two potential uses of casdatifan: treatment after an earlier therapy has failed and treatment at the outset of care. He said the share price partly reflected the second-line opportunity, while the first-line application remained underappreciated.
Arcus shares rose 11% to $24.48 in morning trading on October 20, following the clinical update. That was an intraday price, not a closing quotation.
The analyst’s $4 billion peak unadjusted sales estimate is a forecast, not company revenue or management guidance. Casdatifan remains investigational, and any commercial opportunity depends on further clinical development and regulatory approval.
| Item | Details |
|---|---|
| Second-line combination | Casdatifan plus cabozantinib: median progression-free survival of 14.5 months in 43 patients. |
| Second-line survival | Overall survival at 18 months was 77%, with median follow-up of 21.3 months. |
| Later-line monotherapy | Four pooled cohorts totaling 121 patients had median overall survival of 35 months. |
| Later-line follow-up | Median follow-up was 28 months; 52% of patients had received at least three prior treatment lines. |
What the clinical update established
The company’s October 2026 ARC-20 announcement described results across first-, second- and later-line treatment settings, all using a September 4, 2026 data cutoff. ARC-20 is evaluating casdatifan, an HIF-2α inhibitor, alone and in combinations for clear cell renal cell carcinoma.
In 30 previously untreated patients receiving casdatifan plus zimberelimab, progression-free survival was 86% at six months and 69% at 12 months. Median follow-up was 11.5 months, and the confirmed objective response rate was 50%. Progression-free survival measures time without disease worsening or death; response rate measures the proportion of patients whose tumors shrink sufficiently to meet trial criteria.
Arcus compared these findings with third-party benchmarks for existing treatments. Those comparisons were not head-to-head tests: differences in patient populations, study designs and sample sizes limit conclusions about relative efficacy. The company reported no unexpected safety signals at the data cutoff, but the drug’s safety and efficacy have not been established.
Phase 3 trials will test the broader development case
Arcus said PEAK-20, a planned first-line Phase 3 trial of casdatifan with ipilimumab and nivolumab, remained on track to begin by year-end 2026. That regimen differs from the two-drug casdatifan–zimberelimab combination highlighted in the first-line results.
The ongoing Phase 3 PEAK-1 study is evaluating casdatifan plus cabozantinib against cabozantinib in immunotherapy-experienced patients. Arcus also plans a registrational trial of casdatifan plus tivozanib against tivozanib.
These trials are the next step toward testing the commercial thesis behind Mizuho’s assessment. The encouraging ARC-20 findings do not establish that later studies will reproduce the results or that casdatifan will receive approval.
Conclusion
The next scheduled development milestone is the planned launch of PEAK-20 by the end of 2026. Its initiation would advance Arcus’s first-line strategy, while the clinical and commercial outcomes underlying Mizuho’s forecast remain uncertain.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
